Anti-VAPA antibody [EPR13589(B)] - N-terminal,Abcam,AB181067
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
WB, IHC-P
Platform ID
BAB259574638
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Endoplasmic reticulum (ER)-anchored protein that mediates the formation of contact sites between the ER and endosomes via interaction with FFAT motif-containing proteins such as STARD3 or WDR44 (PubMed : 32344433, PubMed : 33124732). STARD3-VAPA interaction enables cholesterol transfer from the ER to endosomes (PubMed : 33124732). Via interaction with WDR44 participates in neosynthesized protein export (PubMed : 32344433). In addition, recruited to the plasma membrane through OSBPL3 binding (PubMed : 25447204). The OSBPL3-VAPA complex stimulates RRAS signaling which in turn attenuates integrin beta-1 (ITGB1) activation at the cell surface (PubMed : 25447204). With OSBPL3, may regulate ER morphology (PubMed : 16143324). May play a role in vesicle trafficking (PubMed : 11511104, PubMed : 19289470). See full target information VAPA
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.